Scientists studied aggressive uterine cancers to see how two important proteins, HER2 and FOLR1, might be connected. They looked at tissue samples from 62 patients and found that when one protein was high, the other was more likely to be high too. This discovery could help doctors choose better treatments for women with this type of cancer, since new medicines that target these proteins are becoming available. The research focused on the most serious types of uterine cancer that are harder to treat with standard therapies.
The Quick Take
- What they studied: Whether two proteins called HER2 and FOLR1 appear together in aggressive uterine cancers
- Who participated: 291 tissue samples from 62 women with high-grade uterine cancer
- Key finding: When HER2 protein levels were high, FOLR1 was twice as likely to also be high (12% vs 5%)
- What it means for you: This may help doctors predict which patients could benefit from newer targeted cancer treatments, though more research is needed